Read the receipt.
- Displayed amount
- $224 /mo from
- Delivery route
- Injection
- Product status
- Compounded prescription
- Membership in this figure
- See provider inclusions and terms
- Quantity
- Confirm the exact supplied quantity
- Upfront commitment
- Confirm the initial charge and billing period
Confirm taxes, diagnostics and any costs not specified in the quote.
Sources: Ivím — individualized GLP-1 program, FDA — compounding questions and answers
What this price means.
This is an included-program starting price, but the public headline does not fix your initial charge or term. Ask for the complete payment schedule. The provider’s cross-study outcome comparison is not a head-to-head trial and does not establish clinical superiority over other services.
Sources: Ivím — individualized GLP-1 program, FDA — compounding questions and answers
The product context.
Zepbound is an FDA-approved tirzepatide medicine. Its approved uses and contraindications are defined in its prescribing information. A compounded preparation has not undergone FDA approval. Manufacturer offers for one device cannot be assumed to apply to another device or to every insurance situation.
Sources: Zepbound — prescribing information, FDA — concerns with unapproved GLP-1 drugs
Before you pay.
What will actually be charged today?
Confirm the initial charge and billing period. Request the full amount due today, its supply period, the next charge date and the renewal amount. The displayed price is a sourced offer, not a personalized invoice.
Is this a clinical recommendation?
No. This review covers public product and price information. Eligibility, treatment choice and the prescribed amount require an appropriate clinician. We have not tested this product.
What should I compare it with?
Start with the same ingredient, route, supplied quantity and billing term. Add any separate care or membership fees. Differences in product approval or formulation remain meaningful even when prices are similar.
Follow the evidence
Sources & price notes
Each source retains its own check date. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- Ivím — individualized GLP-1 program ↗
Official public information; price and terms checked October 8, 2026.
Checked October 8, 2026
- FDA — compounding questions and answers ↗
Clinical and regulatory context. A compounded preparation is not FDA-approved.
Checked October 8, 2026
- Zepbound — prescribing information ↗
Approved uses, contraindications and warnings.
Checked October 8, 2026
- FDA — concerns with unapproved GLP-1 drugs ↗
Safety, dosing errors, salt forms and misleading online marketing. Regulatory page rechecked October 9, 2026; retain distinctions between approval, risk information and compounding nominations.
Checked October 9, 2026